This note responds to the Department of Health's review, led by Professor Mike Richards, into the consequences of additional private drugs for NHS care.
How are top-ups distinct from other charges in the NHS and why have they become such a contentious issue now? This briefing gives some background on the relevant legislation and guidance in this area. [Introduction]
The National Institute for Health and Clinical Excellence (NICE) is acknowledged as a world leader in its field, yet the prevailing media image of NICE is as a controversial mechanism for denying patients expensive new drugs. Teresa Poole looks at how NICE appraises new and existing drugs through clinical and ...